Brought to you by:
VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism
A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional radiologist Konstantinos Katsanos, MD, that reported a heightened risk of major amputation after use of paclitaxel-coated balloons…
Amputation rates higher for people with PAD who are poor or Black
Poverty and Black race were associated with higher rates of lower-leg amputation among people with peripheral arterial disease (PAD) who live in metropolitan areas, according to new research published today in a special issue of the Journal of the American Heart Association (JAHA), an open…
Vascular Quality Initiative launches ‘My PAD’ pilot
The Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) has created “My PAD,” a pilot program for collecting patient-reported outcomes (PROs) from patients undergoing endovascular treatment for peripheral arterial disease (PAD). Traditional outcomes such as patency and reintervention may…
FDA approves expanded PAD indication for rivaroxaban plus aspirin
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease (PAD) indication for the Xarelto (rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) to…
Veterans with claudication who undergo revascularization ‘significantly more likely to have major amputation than those who do not’
Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of undergoing subsequent amputation compared to those who did not, researchers at Stanford University report. Furthermore, Intervention…
‘Let’s move on to solutions,’ keynote speaker tells diversity, equity and inclusion focus session
Lee Kirksey, MD, issued an unapologetic apology of sorts at the outset of his discussion of diversity, equity and inclusion (DEI) issues. “If I ruffle any feathers I apologize, but I think it’s a conversation that’s important to have,” said…
Colombian researchers report positive 24-month results for VenoValve
Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual Meeting (VAM) in San Diego on Thursday afternoon. Researchers from Bogota, Colombia, revealed that patients treated…
Research letter highlights low adoption of supervised exercise therapy for PAD
A research letter published in Circulation: Cardiovascular Quality and Outcomes highlights a “very low” utilization of supervised exercise therapy (SET) in symptomatic peripheral arterial disease (PAD) patients during the first 19 months after approval by the Centers for Medicare & Medicaid Services (CMS)…
VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass regardless of conduit type
“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev, MD, during the William J. von Liebig Forum at the Vascular Annual Meeting (VAM) in San…
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment
MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee (BTK) disease. According to a MedAlliance press release, Selution SLR is the first DEB to be…